Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Bringing Medicines to Market Faster Through Analytics & Machine Learning

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Traditional medicine isn’t generally taken very seriously in the United States. However, Dr. Andrea Small-Howard, President and CSO at GB Sciences explained that “65% of the world still use traditional medicine either as their sole medicine or in conjunction with Western medicine.” Depending on the source, traditional plant-based medicine dates back as far as 60,000 years whereas Western medicine is a mere 3,000 years old.

Kevin Stevenson, I Don’t Care podcast host, sat down with the distinguished Dr. Small-Howard to discuss her work in the plant-based medicine industry. Dr. Small-Howard will also discuss the digital transformation curve with GB Sciences AI-based drug discovery platform PhAROS. This podcast is of great interest due in part to Dr. Small-Howard’s extensive resume. In fact, it is so extensive that the following introduction from her LinkedIn profile barely highlights her expertise.

“Dr. Andrea Small-Howard has 25 years of scientific research and executive experience in the biopharma industry supervising research & development, manufacturing, and quality control divisions in the US and China. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (‘US FDA’), and orchestrated commercial licensing deals.”

Listeners might think that they would not be able to understand or relate to such a well-educated scientific mind, but nothing could be further from the truth. Dr. Small-Howard is an engaging speaker filled with enthusiasm for her chosen line of work and her mission to normalize plant-based medicine in the United States.

“My background is in biochemistry, so I sort of see the world through a different lens and I’ve always been obsessed with the power of plant-based medicines. Traditional medicine is often overlooked as being a really powerful force here in the United States,” said Dr. Small-Howard. The doctor joined GB Sciences in 2014 to take plant-based medicine to the next level by utilizing science to maximize the potential of the cannabis plant.

More Like This Story:

Behavioral Health Is Stepping Out of the Shadows of Healthcare

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI says roughly 10,000 AI agents produced a proposed Navier–Stokes solution in 88 hours, followed by Lean verification. For healthcare and life sciences, the immediate signal is a research workflow built around parallel agents, code execution, provenance and formal checking—not a ready-made clinical simulator.

  • 01OpenAI's result is a proposed proof under review, not a new clinical simulation product.
  • 02The near-term B2B signal is a coordinated research stack combining agents, code and formal verification.
  • 03Healthcare buyers should evaluate provenance, reproducibility, security and cost per validated result.

Sep 9, 2026

Get  checked out

Get checked out

Seeking medical evaluation immediately after a vehicle crash, regardless of how you feel, is essential because adrenaline can mask serious injuries for hours or even up to a full day. A same-day medical visit creates a documented paper trail tied to the accident date, which protects against insurance companies disputing injury claims and denying compensation.

  • 01Feeling fine immediately after a vehicle crash may not accurately reflect one's health condition.
  • 02The body's response to stress can delay the onset of injury symptoms.
  • 03Seek medical evaluation after a crash, even if injuries aren't immediately apparent.

Sep 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512